Stockscreener 앱 받기
1.215
1.23%
-0.005
전일 마감가:
$1.22
열려 있는:
$1.21
하루 거래량:
41,748
Relative Volume:
0.16
시가총액:
$65.34M
수익:
$96.63M
순이익/손실:
$-63.32M
주가수익비율:
-0.8322
EPS:
-1.46
순현금흐름:
$-54.55M
1주 성능:
-8.02%
1개월 성능:
+2.99%
6개월 성능:
-61.00%
1년 성능:
-70.17%
1일 변동 폭
$1.19
$1.325
1주일 범위
$1.16
$1.34
52주 변동 폭
$1.01
$4.65
아코야 바이오 Stock (AKYA) Company Profile
명칭
Akoya Biosciences Inc
전화
855.896.8401
주소
100 CAMPUS DRIVE, MARLBOROUGH
AKYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.21 | 65.34M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
534.92 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.12 | 48.46B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
97.98 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
241.35 | 35.24B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.49 | 16.39B | 3.90B | 392.30M | 288.10M | 1.95 |
아코야 바이오 Stock (AKYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2024-08-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-02-02 | 개시 | UBS | Buy |
| 2022-11-03 | 개시 | CapitalOne | Overweight |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-06-22 | 개시 | BTIG Research | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-05-11 | 개시 | Canaccord Genuity | Buy |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Morgan Stanley | Overweight |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
아코야 바이오 주식(AKYA)의 최신 뉴스
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Canaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
Quanterix Acquisition of Akoya Biosciences (AKYA) Faces Challenges | AKYA Stock News - GuruFocus
Quanterix, Akoya Biosciences Amend Merger Deal - marketscreener.com
Akoya stock falls on amended Quanterix merger deal (AKYA) - Seeking Alpha
Quanterix Revises Merger Terms with Akoya Biosciences - TipRanks
Merger Amendment: Changes to Quanterix and Akoya Biosciences (AK - GuruFocus
Quanterix And Akoya Biosciences Announce Amended Merger Agreement - marketscreener.com
Canaccord Adjusts Price Target for Akoya Biosciences (AKYA) | AK - GuruFocus
Quanterix and Akoya Biosciences Announce Amended Merger Agreement - Business Wire
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now - GlobeNewswire Inc.
Akoya Biosciences introduces new assay for breast cancer ADC development By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pacific Premier Bancorp, Inc. (NasdaqPPBI), Southern States Bancshares, Inc. (NasdaqSSBK), Akoya Biosciences, Inc. (NasdaqAKYA) - TradingView
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Res - GuruFocus
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Research | AKYA Stock News - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development - Investing.com Australia
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - The Manila Times
Akoya Biosciences Expands Biopharma Service Portfolio with - GlobeNewswire
Akoya Biosciences and Enable Medicine Launch the Largest - GlobeNewswire
Revolutionary Breast Cancer Detection: Akoya's New ADC Assay Targets HER2-Low and TROP2 Biomarkers - Stock Titan
Akoya Biosciences Collaborates with Singapore Translational Cancer Consortium on SUPER Study to Enhance Immunotherapy Response Analysis - Nasdaq
Akoya Biosciences and Singapore Translational Cancer - GlobeNewswire
Major Cancer Research Breakthrough: How 200 Patient Study Could Transform Immunotherapy Treatment Success - Stock Titan
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore - The Manila Times
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of GB, YOTA, PORT, AKYA to Act - The Malaysian Reserve
7.7% Stakeholder Fights Quanterix-Akoya Merger: Claims Board Conflicts and Shareholder Value Destruction - Stock Titan
Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders - Business Wire
Akoya Biosciences (NASDAQ:AKYA) Given New $1.65 Price Target at Piper Sandler - Defense World
Tikvah Management Calls on Quanterix to Explain the Egregious Te - GuruFocus
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Bluefield Daily Telegraph
Quanterix Faces Investor Backlash: $30M Convertible Notes Deal Under Fire - Stock Titan
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences | QTRX Stock News - GuruFocus
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges - Investing.com India
Quanterix Under Fire: Top Investor Warns of 'Value Destructive' $30M Deal with Struggling Akoya - Stock Titan
Akoya BiosciencesOn April 2, Entered Securities Purchase Agreement With Quanterix Corporation - MarketScreener
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Akoya Biosciences and Team SAMBAI Announce Selection of the - GlobeNewswire
Akoya Biosciences And Team SAMBAI Select PhenoCycler-Fusion For Cancer Equity Research - Nasdaq
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Yahoo Finance
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Decreases By 30.8% - The AM Reporter
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 30.8% in March - Defense World
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges - Investing.com India
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Akoya Biosciences’ (AKYA) Equal Weight Rating Reaffirmed at Stephens - Defense World
Akoya Biosciences Shares Fall After Downgrade From Stephens - MarketScreener
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80 - Marketscreener.com
아코야 바이오 (AKYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아코야 바이오 주식 (AKYA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
0.67%
0.53%
자본화:
|
볼륨(24시간):